Professor Massimo Pieri works at the Department of Experimental Medicine and Surgery, Clinical Biochemistry of the University of Rome “Tor Vergata”. He obtained his Bachelor's of Biology at the University of Rome “La Sapienza”. Since 2002, his research was aimed at studying neuronal excitability, ionic channels modulation, and the mechanisms of action of drugs on the Central Nervous System using electrophysiological techniques on animal models. Another major field of interest has been the Amyotrophic Lateral Sclerosis (ALS). In this respect, he has focused on the altered functionality of the voltage-dependent ionic channels and ionotropic receptors in a genetic model of ALS. In 2006, he obtained a Ph.D. in “Neuroscience” at the University of Rome “Tor Vergata.” Since 2010. he works in the Laboratory of Clinical Biochemistry and Clinical Molecular Biology of the University Hospital of Tor Vergata and his research has expanded in this field. In 2016, he obtained the Specialization in Clinical Biochemistry and, in 2018, he received the National Scientific Qualification for Associate Professor 05 / E3 of Clinical Biochemistry and Clinical Molecular Biology.
Professor Massimo Pieri works at the Department of Experimental Medicine and Surgery, Clinical Biochemistry of the University of Rome “Tor Vergata”. He obtained his Bachelor's of Biology at the University of Rome “La Sapienza”. Since 2002, his research was aimed at studying neuronal excitability, ionic channels modulation, and the mechanisms of action of drugs on the Central Nervous System using electrophysiological techniques on animal models. Another major field of interest has been the Amyotrophic Lateral Sclerosis (ALS). In this respect, he has focused on the altered functionality of the voltage-dependent ionic channels and ionotropic receptors in a genetic model of ALS. In 2006, he obtained a Ph.D. in “Neuroscience” at the University of Rome “Tor Vergata.” Since 2010. he works in the Laboratory of Clinical Biochemistry and Clinical Molecular Biology of the University Hospital of Tor Vergata and his research has expanded in this field. In 2016, he obtained the Specialization in Clinical Biochemistry and, in 2018, he received the National Scientific Qualification for Associate Professor 05 / E3 of Clinical Biochemistry and Clinical Molecular Biology.